TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-ce…
$59.83+3.18%
报价 2026-11-06
市值
$9.16B
EV
$7.89B
PE (TTM)
15.5x
预期 PE (FY2026)
59.9x
52 周区间距高点 -2.9%
$26.94$61.63
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| TGTXTG Therapeutics, Inc. | $9.16B | +3.2% | +51.9% | 83% | 15.5x | 50.3x | – | |
| KYMRKymera Therapeutics, Inc. | $11.25B | +2.8% | +48.6% | 100% | – | – | – | |
| PCVXVaxcyte, Inc. | $10.06B | +3.2% | +4900.0% | 0% | – | – | – | |
| KRYSKrystal Biotech, Inc. | $8.92B | +0.2% | +34.7% | 92.6% | 35.3x | 40.7x | 46.7x | |
| PTGXProtagonist Therapeutics, Inc. | $8.54B | -2.4% | +959.8% | 99.2% | – | – | 147.6x | |
| ARWRArrowhead Pharmaceuticals, Inc. | $8.22B | +1.2% | -28.9% | 100% | – | – | – | |
| ALKSAlkermes plc | $7.7B | +3.1% | – | 86.6% | 55.6x | 35.6x | – | |
| IMVTImmunovant, Inc. | $6.31B | +7.5% | -37.1% | 0% | – | – | – | |
| PTCTPTC Therapeutics, Inc. | $5.47B | -0.4% | -37.6% | 92.4% | – | 33.3x | – | |
| 同行中位数 | – | – | +34.7% | 92.5% | 45.5x | 35.6x | 97.2x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。